Elevation Oncology, Inc. financial data

Symbol
ELEV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
101 Federal Street, Suite 1900, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
14ner Oncology, Inc. (to 7/19/2019)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.72K % +147%
Debt-to-equity 48.7 % -29%
Return On Equity -62.2 % +24.1%
Return On Assets -41.8 % +13.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.2M shares +8.38%
Common Stock, Shares, Outstanding 59.1M shares +39.4%
Entity Public Float 135M USD +156%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 57.3M shares +56.8%
Weighted Average Number of Shares Outstanding, Diluted 57.3M shares +56.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 28.6M USD +12.4%
General and Administrative Expense 16.1M USD +8.07%
Operating Income (Loss) -44.7M USD +1.63%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.4M USD +2.7%
Income Tax Expense (Benefit) 43K USD +43.3%
Net Income (Loss) Attributable to Parent -44.5M USD +2.67%
Earnings Per Share, Basic -0.78 USD/shares +37.6%
Earnings Per Share, Diluted -0.78 USD/shares +37.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.5M USD +0.42%
Marketable Securities, Current 43.7M USD +29.2%
Assets, Current 94.7M USD +7.69%
Property, Plant and Equipment, Net 34K USD -42.4%
Other Assets, Noncurrent 866K USD -18.9%
Assets 95.6M USD +7.34%
Accounts Payable, Current 559K USD +10.3%
Accrued Liabilities, Current 3.91M USD +7.42%
Liabilities, Current 4.47M USD +7.77%
Liabilities 35.6M USD +3.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax 61K USD +578%
Retained Earnings (Accumulated Deficit) -240M USD -22.7%
Stockholders' Equity Attributable to Parent 60M USD +9.52%
Liabilities and Equity 95.6M USD +7.34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.58M USD +43.1%
Net Cash Provided by (Used in) Financing Activities 30.3M USD +13905%
Net Cash Provided by (Used in) Investing Activities 20.7M USD -22.2%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 59.2M shares +39.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.4M USD +314%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 49.5M USD +0.42%
Interest Paid, Excluding Capitalized Interest, Operating Activities 887K USD +66.7%
Deferred Tax Assets, Valuation Allowance 60.3M USD +31.3%
Deferred Tax Assets, Gross 60.3M USD +31.3%
Depreciation 10K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.4M USD +2.42%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +30.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 301M USD +19.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 4K USD +33.3%
Share-based Payment Arrangement, Expense 4.28M USD +28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%